ATE336231T1 - Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung - Google Patents

Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung

Info

Publication number
ATE336231T1
ATE336231T1 AT02801623T AT02801623T ATE336231T1 AT E336231 T1 ATE336231 T1 AT E336231T1 AT 02801623 T AT02801623 T AT 02801623T AT 02801623 T AT02801623 T AT 02801623T AT E336231 T1 ATE336231 T1 AT E336231T1
Authority
AT
Austria
Prior art keywords
solvent
mixing zone
precipitation
producing crystalline
recirculating
Prior art date
Application number
AT02801623T
Other languages
English (en)
Inventor
James E Hitt
Christopher J Tucker
Jonathan C Evans
Cathy A Curtis
Sonke Svenson
Original Assignee
Dow Global Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc filed Critical Dow Global Technologies Inc
Application granted granted Critical
Publication of ATE336231T1 publication Critical patent/ATE336231T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02801623T 2001-08-29 2002-08-27 Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung ATE336231T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31556001P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
ATE336231T1 true ATE336231T1 (de) 2006-09-15

Family

ID=23224987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801623T ATE336231T1 (de) 2001-08-29 2002-08-27 Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung

Country Status (6)

Country Link
US (1) US20030049323A1 (de)
EP (1) EP1423096B1 (de)
AT (1) ATE336231T1 (de)
CA (1) CA2458889C (de)
DE (1) DE60214012T2 (de)
WO (1) WO2003032951A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450748A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
DE10214031A1 (de) * 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
CN100434133C (zh) * 2003-04-29 2008-11-19 欧加农股份有限公司 反溶剂凝固方法
CA2526454C (en) 2003-05-22 2013-08-13 Applied Nanosystems B.V. Gel-assisted production of small particles
CN1878602A (zh) * 2003-11-28 2006-12-13 三菱化学株式会社 有机化合物微粒的制造方法
US9682043B2 (en) * 2003-12-09 2017-06-20 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
EP1730516A1 (de) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Verfahren und vorrichtung zur bewertung pharmazeutischer zusammensetzungen
WO2006026502A1 (en) 2004-08-27 2006-03-09 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
WO2006028074A1 (ja) * 2004-09-07 2006-03-16 Mitsubishi Chemical Corporation 微粒子化された物質の製造方法および微粒子化された物質
CN101360421B (zh) 2005-11-18 2014-06-18 康乃尔研究基金会有限公司 烟酰核苷组合物及其使用方法
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20080193518A1 (en) * 2006-04-28 2008-08-14 Schering Corporation Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
GB0705159D0 (en) 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
EP2162120B1 (de) * 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
EP2231169B1 (de) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
WO2010003811A1 (en) * 2008-07-11 2010-01-14 Basf Se Amphiphilic proteins as morphology modifiers
SG10202010355PA (en) 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
EP2618818A4 (de) * 2010-09-22 2014-10-29 Map Pharmaceuticals Inc Corticosteroidpartikel und herstellungsverfahren dafür
US20120311822A1 (en) * 2011-06-10 2012-12-13 Culkin Joseph B Solute crystallizing apparatus
EP2720680B1 (de) 2011-06-17 2020-02-12 Berg LLC Inhalbierbare pharmazeutische zusammensetzungen
EP2601973A1 (de) 2011-12-09 2013-06-12 Laboratoires SMB SA Trockenpulverformulierung eines Azolderivats zum Inhalieren
DE102012221219B4 (de) * 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
PT108368B (pt) 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
US20190380967A1 (en) * 2017-01-23 2019-12-19 Savior Lifetec Corporation Preparation of microparticles of an active ingredient
CN109011674B (zh) * 2018-09-11 2020-08-11 安徽东至广信农化有限公司 一种用于硝基氯苯制备的蒸酸器
EP4041203A1 (de) 2019-10-10 2022-08-17 Bayer Aktiengesellschaft Verfahren zur herstellung eines nanopartikulären wirkstoffs
WO2026013055A1 (en) * 2024-07-09 2026-01-15 Hovione Farmaciência S.A., Methods and systems for preparing feed solutions for spray drying

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US624617A (en) * 1899-05-09 Insecticide
SU1126202A3 (ru) * 1976-05-28 1984-11-23 Институт Фор Атомэнерги (Фирма) Способ непрерывной многостадийной кристаллизации из раствора
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
ES2078447T3 (es) * 1990-06-15 1995-12-16 Merck & Co Inc Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
DE59701724D1 (de) * 1996-07-05 2000-06-21 Haarmann & Reimer Gmbh Kristallisationsvorrichtung und -verfahren
DE19738085C1 (de) * 1997-09-01 1998-12-03 Basf Ag Verfahren zur Herstellung von Feststoffen durch Fällung
US5908589A (en) * 1997-12-08 1999-06-01 Twenty-First Century Research Corporation Methods for separating catalyst from oxidation mixtures containing dibasic acids
EP0930073B1 (de) * 1998-01-14 2004-08-04 National Research Development Corporation of India Verfahren zur Herstellung eines spermiziden Mittels
US6607651B2 (en) * 1998-09-10 2003-08-19 Cws Parts Company Process and system for treating the discharge stream from an ion exchanger
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
GB9905512D0 (en) * 1999-03-10 1999-05-05 Smithkline Beecham Plc Process
TW526172B (en) * 1999-06-30 2003-04-01 Sumitomo Chemical Co A process for producing pentacyl-type crystalline zeolites and a process for producing ε-caprolactam using the same
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US6756062B2 (en) * 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions

Also Published As

Publication number Publication date
CA2458889C (en) 2011-06-21
WO2003032951A1 (en) 2003-04-24
CA2458889A1 (en) 2003-04-24
DE60214012D1 (de) 2006-09-28
DE60214012T2 (de) 2006-12-21
US20030049323A1 (en) 2003-03-13
EP1423096B1 (de) 2006-08-16
EP1423096A1 (de) 2004-06-02

Similar Documents

Publication Publication Date Title
ATE336231T1 (de) Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung
DE50005599D1 (de) Verfahren zur herstellung von morphologisch einheitlichen mikro- und nanopartikeln mittels eines mikromischers
SE9501384D0 (sv) Process for the preparation of respirable particles
ES2194579B1 (es) Metodo de produccion de fibra que tiene polvo mineral funcional y fibra producida a partir del mismo.
DE60029457D1 (de) Verfahren zur herstellung von feinkörnigen medizinischen substanzen
ATE179886T1 (de) Pharmazeutische zusammensetzung mit einem schmelzbaren traegermaterial und verfahren zu seiner herstellung
ATE199828T1 (de) Verfahren zur konditionierung von substanzen
ATE302786T1 (de) Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
DE50205571D1 (de) Verfahren zur Herstellung von direkt tablettierbaren Beta-Mannit
ATE327737T1 (de) Verfahren zur herstellung von arzneistoffgranulatkörnern, die arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische zubereitungen
DE69625813D1 (de) Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
DE602004015406D1 (de) Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
ATE305000T1 (de) Sysntheseverfahren zur herstellung von indolylquinonen und mono- und bis-indolylquinone, die durch das verfahren hergestellt sind
BR0318104A (pt) Processos para a fabricação de materiais de filtros para água e filtros para água
ATE491463T1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
NO20011634D0 (no) Krystall av diuridintetrafosfat eller salter derav, og fremgangsmåte for fremstilling av samme og fremgangsmåte for fremstilling av nevnte forbindelse
DE602004000665D1 (de) Biologisches Verfahren zur Herstellung eines Hämeisenpräparats und daraus hergestellte Nahrungsmittelprodukte
GB0120123D0 (en) Preparation of microparticles
ATE298567T1 (de) Pharmazeutische zusammensetzung enthaltend ibuprofen und ein verfahren zur deren herstellung
DE50301507D1 (de) 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
SG153663A1 (en) Process for the production of biodegradable, functionalised polymer particles and use thereof as pharmaceutical supports
DE50002706D1 (de) Verfahren zur Herstellung eines Baukörpers
ATE277963T1 (de) Verfahren und vorrichtung zur herstellung von cellulosepartikeln
EP1710251A4 (de) Neues peptid, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die das peptid enthält
ATE421961T1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties